Fair Value Measurements - Schedule of Significant Inputs to the Discounted Cash Flow Technique Used to Value Contingent Consideration for IFM (Details) - Discounted Cash Flow - IFM - Rate	Mar. 31, 2026	Dec. 31, 2025
Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Significant Unobservable Inputs	16.4	15.6
Probability of milestone achievement \| Maximum \| MDA5
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Significant Unobservable Inputs	35	35
Probability of milestone achievement \| Maximum \| NLRP1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Significant Unobservable Inputs	35	35
Probability of milestone achievement \| Minimum \| MDA5
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Significant Unobservable Inputs	5	5
Probability of milestone achievement \| Minimum \| NLRP1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Significant Unobservable Inputs	5	5
Projected milestone timing \| Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Projected milestone timing	11 years 6 months 3 days	11 years 9 months
Projected milestone timing \| Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Projected milestone timing	2 years 6 months	2 years 3 months

Odyssey Therapeutics, Inc. 10-Q